Claris Lifesciences announced its un-audited financial results for the quarter ended March 31, 2013 at its recently held board meeting in Mumbai. The consolidated revenues for the quarter stood at Rs 1,822 million compared to Rs 1,804 million in the same quarter previous year. The consolidated Earnings Before Interest, Depreciation, Taxes and Amortization (EBITDA) stood at Rs 541 million for Q1CY13 against Rs 545 million for the same quarter last year. EBITDA margins stood flat at 30 per cent to net sales.
Consolidated profit after tax for Q1CY13 stood at Rs 155 million as compared to Rs 217 million for the same quarter previous year. The margins have de-grown by 3.5 per cent due to increased depreciation from the IPO capex being put to use this year.
EP News Bureau – Mumbai
